RT Journal Article
SR Electronic
T1 Treatment response and drug retention rates in 24 195 biologic-naïve patients with axial spondyloarthritis initiating TNFi treatment: routine care data from 12 registries in the EuroSpA collaboration
JF Annals of the Rheumatic Diseases
JO Ann Rheum Dis
FD BMJ Publishing Group Ltd and European League Against Rheumatism
SP 1536
OP 1544
DO 10.1136/annrheumdis-2019-215427
VO 78
IS 11
A1 Ørnbjerg, Lykke Midtbøll
A1 Brahe, Cecilie Heegaard
A1 Askling, Johan
A1 Ciurea, Adrian
A1 Mann, Herman
A1 Onen, Fatos
A1 Kristianslund, Eirik Klami
A1 Nordström, Dan
A1 Santos, Maria Jose
A1 Codreanu, Catalin
A1 Gómez-Reino, Juan
A1 Rotar, Ziga
A1 Gudbjornsson, Bjorn
A1 Di Giuseppe, Daniela
A1 Nissen, Michael J
A1 Pavelka, Karel
A1 Birlik, Merih
A1 Kvien, Tore
A1 Eklund, Kari Kalervo
A1 Barcelos, Anabela
A1 Ionescu, Ruxandra
A1 Sanchez-Piedra, Carlos
A1 Tomsic, Matija
A1 Geirsson, Árni Jón
A1 Loft, Anne Gitte
A1 van der Horst-Bruinsma, Irene
A1 Jones, Gareth
A1 Iannone, Florenzo
A1 Hyldstrup, Lise
A1 Krogh, Niels Steen
A1 Hetland, Merete Lund
A1 Østergaard, Mikkel
YR 2019
UL http://ard.bmj.com/content/78/11/1536.abstract
AB Objective To study drug retention and response rates in patients with axial spondyloarthritis (axSpA) initiating a first tumour necrosis factor inhibitor (TNFi).Methods Data from 12 European registries, prospectively collected in routine care, were pooled. TNFi retention rates (Kaplan-Meier statistics), Ankylosing Spondylitis Disease Activity Score (ASDAS) Inactive disease (<1.3), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) <40 mm and Assessment of SpondyloArthritis International Society responses (ASAS 20/40) were assessed at 6, 12 and 24 months.Results A first TNFi was initiated in 24 195 axSpA patients. Heterogeneity of baseline characteristics between registries was observed. Twelve-month retention was 80% (95% CI 79% to 80%), ranging from 71% to 94% across registries. At 6 months, ASDAS Inactive disease/BASDAI<40 rates were 33%/72% (LUNDEX-adjusted: 27%/59%), ASAS 20/40 response rates 64%/49% (LUNDEX-adjusted 52%/40%). In patients initiating first TNFi after 2009, 6097 patients was registered to fulfil ASAS criteria for axSpA, 2935 was registered to fulfil modified New York Criteria for Ankylosing Spondylitis and 1178 patients was registered as having non-radiographic axSpA. In nr-axSpA patients, we observed lower 12-month retention rates (73% (70%–76%)) and lower 6-month LUNDEX adjusted response rates (ASDAS Inactive disease/BASDAI40 20%/50%, ASAS 20/40 45%/33%). For patients initiating first TNFi after 2014, 12-month retention rate, but not 6-month response rate, was numerically higher compared with patients initiating TNFi in 2009–2014.Conclusion A large European database of patients with axSpA initiating a first TNFi treatment in routine care, demonstrated that 27% of patients achieved ASDAS inactive disease after 6 months, while 59% achieved BASDAI <40. Four of five patients continued treatment after 1 year.